Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05438706 | A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05400304 | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma | unknown | — | 900 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 0 |
| Jun 29, 2022 |
| clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05429294 | Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 | unknown | Phase 2 | 209 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05426850 | ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma | unknown | — | 100 | Fudan UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05238363 | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05422547 | Role of Immunoscore® in Stage II-III Colorectal Cancer | unknown | — | 100 | D'Or Institute for Research and EducationOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05397860 | Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05420922 | Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04215471 | NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma(NATION1907II) | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04174781 | Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05411926 | Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma | unknown | — | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05002452 | Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC | unknown | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05400681 | Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer(LIPAC) | unknown | — | 200 | Sonke DetlefsenOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05269056 | Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05402046 | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms(CAMELLIA) | unknown | N/A | 605 | MelanomaPRO, RussiaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05395611 | Exhaled Breath Particles in Lung Cancer | unknown | — | 300 | Lund University HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05391867 | Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma | unknown | N/A | 70 | Sir Salimullah Medical College Mitford HospitalOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05381636 | Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT05383066 | Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer | unknown | — | 490 | Peking University First HospitalOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT03741517 | Biomarker Study of Pancreatic Neuroendocrine Tumours | unknown | — | 40 | Uppsala UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05376943 | Possible Differences in HCC Course Depending on DAA Treatment | unknown | — | 100 | Medical University of WarsawOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05374252 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | unknown | Phase 3 | 102 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT05372302 | Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)(CICERONE) | unknown | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05339321 | Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC | unknown | Phase 1 | 36 | Peking Union Medical College HospitalOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02781285 | Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score(ESCOTCMAGCPS) | unknown | — | 1,500 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05363722 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 80 | Shanghai Zhongshan HospitalOTHER | 0 | May 6, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05111366 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection(ALTER-H006) | unknown | Phase 2 | 37 | Xianhai MaoOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | unknown | Phase 1 | 20 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05290220 | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT04487704 | Camrelizumab Utilization on Patients With Advanced Liver Cancer | unknown | N/A | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353894 | Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers | unknown | Phase 1 | 27 | Genoscience PharmaINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02748707 | Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study(ERLO-XIB) | unknown | Phase 2 | 64 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 28, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jun 30, 2022source: clinicaltrials